期刊文献+

EGFR/CerbB-2/MAPK介导乳腺癌三苯氧胺耐药细胞的生长 被引量:3

下载PDF
导出
摘要 目的探讨乳腺癌三苯氧胺(TAM)获得性抵抗细胞的生长调节途径及三苯氧胺(TAM)获得性抵抗的发生机制。方法构建TAM抵抗的人乳腺癌细胞系(MCF-7/TAMR),RT-PCR、Westernblot及免疫细胞化学方法比较MCF-7/TAMR与MCF-7/WT细胞系中EGFR(CerbB-1)、CerbB-2、CerbB-3、CerbB-4mRNA及蛋白表达的不同。结果与MCF-7/WT细胞相比,MCF-7/TAMR细胞中表皮生长因子受体EGFR的mRNA增加6倍(P<0.05),蛋白增加3倍(P<0.05);CerbB-2的mRNA增加3倍(P<0.05),蛋白增加1.5倍(P<0.05);CerbB-3在两种细胞中的表达相似;CerbB-4未能检测到;MCF-7/TAMR细胞中MAPK活化水平增高;基础条件下,MCF-7/TAMR细胞中磷酸化的EGFR/CerbB-2,EGFR/CerbB-3异二聚体与细胞外信号调节激酶磷酸化水平增高有关;Herceptin处理MCF-7/TAMR细胞,阻滞了CerbB-2受体异二聚体的形成及磷酸化,降低了细胞外信号调节激酶的活性,明显抑制了细胞的生长。结论表皮生长因子受体特异性配体的自分泌释放作用诱导EGFR/CerbB-2二聚体形成及下游细胞外信号调节激酶(MAPK)的活化引起MCF-7/TAMR细胞的生长。
出处 《实用肿瘤学杂志》 CAS 2005年第2期143-146,共4页 Practical Oncology Journal
基金 哈尔滨医科大学附属肿瘤医院科研启动基金资助项目(JJ2005001)
  • 相关文献

参考文献9

  • 1Schafer JM, Bentrem DJ, Takei H, et al. A mechanism of drug resistance to tamoxifen in breast cancer [J]. Steroid Biochem Mol Biol,2002 Dec;83(1 - 5):75~83.
  • 2Knowlden JM, Gee JM, Seery LT, et al. C-erbB3 and C- erbB-4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer [J]. Oncogene, 1998;17:1949~1957.
  • 3Knowlden JM, Gee JM, Bryant S, et al. Use of reverse transcription -polymerase chain reaction methodology to detect estrogen - regulated gene expression in small breast cancer specimens [J]. Clin Cancer Res,1997;3:2165~2172.
  • 4DeFazio A, Chiew Y- E, Sini RL, et al. Expression of C- erbB receptors, heregulin and oestrogen receptor in human breast cell lines [J]. Int J Cancer, 2000;87:487~498.
  • 5McClelland RA, Barrow D, Madden T, et al. Enhanced epidermal growth factor receptor signalling in MCF7 breast cancer cells following long- term culture in the presence of the pure antioestrogen ICI 182,780 (Faslodex) [J]. Endocrinology, 2001;142:2776~2788.
  • 6Larsen SS, Egebald M, Jaattela M, et al. Acquired antiestrogen resistance in MCF- 7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB - family [J]. Breast Cancer Res Treat, 1999;58:41~56.
  • 7Graus- Porta D, Beerli RR, Daly JM, et al. ErbB- 2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling [J]. EMBO J, 1997;16:1647~1655.
  • 8Kurokawa H, Lenferink AEG, Simpson JF, et al. Inhibition of HER-2/neu ( erbB - 2 ) and mitogen -activated protein kinases enhances tamoxifen action against HER2- overexpressing, tamoxifen- resistant breast cancer cells [J]. Cancer Res, 2000;60:5887~5894.
  • 9McClelland RA, Barrow D, Madden T, et al. Enhanced epidermal growth facor receptor signalling in MCF- 7 breast cancer cells following long- term culture in the presence of the pure antioestrogen ICI 182,780 (Faslodex) [J]. Endocrinology, 2001;142:2776~2788.

同被引文献23

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部